Key result
Within 6 months, patients receiving dabigatran alone showed reductions in CHA2DS2-VASc (2.58 to 1.94) and HAS-BLED scores (1.15 to 0.84), with lower background risks than the dabigatran plus antiplatelet group.
Why the study?
The study aimed to determine and compare the risk of stroke and bleeding after initiating dabigatran therapy, specifically assessing whether concurrent antiplatelet use impacts its safety and efficacy profile.
Does dabigatran alone compared to dabigatran with an antiplatelet improve stroke and bleeding risk scores in patients prescribed dabigatran?
Cohort
No
Does dabigatran alone compared to dabigatran with an antiplatelet improve stroke and bleeding risk scores in patients prescribed dabigatran?
Both dabigatran alone and dabigatran plus antiplatelet were associated with reductions in calculated stroke and bleeding risk scores over 6 months, though the combination group had higher baseline risk.
No takes yet. Share an insight, caveat, or question.
May inform dabigatran dosing in nonvalvular AF; leaves open need for prospective trials to confirm stroke and bleeding risks.
Thomas et al. (2022) conducted a cohort in Nonvalvular atrial fibrillation. Dabigatran alone vs. Dabigatran with an antiplatelet was evaluated on CHA2DS2-VASc and HAS-BLED scores. Within 6 months, patients receiving dabigatran alone showed reductions in CHA2DS2-VASc (2.58 to 1.94) and HAS-BLED scores (1.15 to 0.84), with lower background risks than the dabigatran plus antiplatelet group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: